Netherlands Journal

netherlands journal of critical care
Invasive aspergillosis is also more common than generally appreciated,
especially in immune-compromised patients, and in view of
the even higher mortality assoiciated with this situation the need for
better treatments may be even greater here. The potential place for
HSP90 inhibition remains to be determined for this indication.
References
1. Eggimann P, Garbino J, Pittet D. Epidemiology of Candida
species infections in critically ill non-immunosuppressed
patients. Lancet Infect Dis 2003; ;3:685-702
(Review).
2. Eggimann P, Garbino J, Pittet D. Management of Candida
species infections in critically ill patients. Lancet
Infect Dis 2003; 3:772-85 (Review.)
3. Snydman DR.Shifting patterns in the epidemiology
of nosocomial Candida infections. Chest 2003;123
(Suppl):500S-503S.
4. Kontoyiannis DP, Lewis RE. Antifungal drug resistance
of pathogenic fungi. Lancet 2002; 359:1135-44 (Review).
5. Denning DW. Echinocandin antifungal drugs. Lancet
2003; 362:1142-51 ( Review).
6. Pappas PG, Rex JH, Lee J, Hamill RJ, Larsen RA, Powderly
W, Kauffman CA, Hyslop N, Mangino JE, Chapman S,
Horowitz HW, Edwards JE, Dismukes WE; NIAID Mycoses
Study Group. A prospective observational study of
candidemia: epidemiology, therapy, and influences on
mortality in hospitalized adult and pediatric patients.
Clin Infect Dis 2003;37:634-43.
7. Volk HD, Reinke P, Döcke WD. Clinical aspects: from
systemic inflammation to ‘immunoparalysis’. Chem
Immunol 2000;74:162-177.
8. Bone RC. Sir Isaac Newton, sepsis, SIRS, and CARS. Crit
Care Med 1996;24:1125-1128.
9. Kox WJ, Bone RC, Krausch D, Döcke WD, Kox SN, Wauer
H, Egerer K, Querner S, Asadullah K, van Baehr R,
Volk HD. Interferon gamma-1b in the treatment of
compensatory anti inflammatory response syndrome.
A new approach: proof of principle. Arch Intern Med
1997;157:389-393.
10. Adrie C, Pinsky MR. The inflammatory balance in human
sepsis. Intensive Care Med 2000;26:364-375 .
11. Jarvis WR. Epidemiology of nosocomial fungal infections,
with emphasis on Candida species.
Clin Infect Dis 1995; 20:1526–30.
12. Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial
infections in medical intensive care units in the
United States. Crit Care Med 1999; 27:887–92.
13. Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial
infections in combined medical-surgical intensive
care units in the United States. Infect Control Hosp
Epidemiol 2000; 21:510–15.
14. Wisplinghoff H, Bischoff T, Tallent SM,Seifert H, Wenzel
RP, Edmond MB. Nosocomial bloodstream infections in
US hospitals: analysis of 24,179 cases from a prospective
nationwide surveillance study. Clin Infect Dis
2004;39:309-17.
15. Wisplinghoff H, Seifert H, Tallent SM, Bischoff T, Wenzel
RP, Edmond MB. Nosocomial bloodstream infections in
pediatric patients in United States hospitals: epidemiology,
clinical features and susceptibilities. Pediatr Infect
Dis J 2003;22:686-91.
16. Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner
C. The epidemiology and attributable outcomes of
candidemia in adults and children hospitalized in the
United States: a propensity analysis. Clin Infect Dis
2005; 41:1232–9.
17. Vincent JL, Bihari DJ, Suter PM, Bruining HA, White J,
Nicolas-Chanoin MH, Wolff M, Spencer RC, Hemmer
M.The prevalence of nosocomial infection in intensive
care units in Europe. Results of the European Prevalence
of Infection in Intensive Care (EPIC) Study. EPIC
International Advisory Committee. JAMA 1995;274:639-
44.
18. Geffers C, Zuschneid I, Sohr D, Ruden H, Gastmeier P.
Microbiological isolates associated with nosocomial
infections in intensive care units: data of 274 intensive
care units participating in the German Nosocomial
Infections Surveillance System (KISS). Anasthesiol
Intensivmed Notfallmed Schmerzther 2004;39:15-9.
[Article in German].
19. Groot AJ, Geubbels EL, Beaumont MT, Wille JC, de Boer
AS. Hospital infections and risk factors in the intensive
care units of 16 Dutch hospitals, results of surveillance
of quality assurance indicators] Ned Tijdschr Geneeskd
2001;145:1249-54. Dutch.
20. Fridkin SK, Jarvis WR. Epidemiology of nosocomial fungal
infections. Clin Microbiol Rev 1996;9:499–511.
21. Wenzel RP. Nosocomial candidemia: risk factors and
attributable mortality. Clin Infect Dis 1995;20:1531–4.
22. Morgan J, Meltzer MI, Plikaytis BD, et al. Excess mortality,
hospital stay, and cost due to candidemia: a
case-control study using data from population-based
candidemia surveillance. Infect Control Hosp Epidemiol
2005;26:540–7.
23. Friedkin SK. Candidemia is Costly - Plain and Simple.
Clinical Inf Dis 2005;41:
24. Vogeser M, Haas A, Aust D, Ruckdeschel G. Postmortem
analysis of invasive aspergillosis in a tertiary care hospital.
Eur J Clin Microbiol Infect Dis 1997; 16:1-6.
25. Groll AH, Shah PM, Mentzel C, et al. Trends in the postmortem
epidemiology of invasive fungal infections at a
university hospital. J Infect 1996; 33:23–32.
26. Hartemink KJ, Paul MA, Spijkstra JJ, Girbes AR, Polderman
KH. Immunoparalysis as a cause for invasive
aspergillosis? Intensive Care Med 2003;29:2068-71.
27. Spellberg BJ, Filler SG, Edwards JE Jr. Current treatment
strategies for disseminated candidiasis. Clin Infect Dis
2006;42:244-51.
28. Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya
L, Smietana J, Lupinacci R, Sable C, Kartsonis
N, Perfect J; Caspofungin Invasive Candidiasis Study
Group. Comparison of caspofungin and amphotericin B
for invasive candidiasis. N Engl J Med 2002; 347:2020-9.
29. Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE,
Walsh TJ, Edwards JE; Infectious Diseases Society of
America. Guidelines for treatment of candidiasis. Clin
Infect Dis 2004;38:161-89.
30. Kullberg BJ, Sobel JD, Ruhnke M, Pappas PG, Viscoli C,
Rex JH, Cleary JD, Rubinstein E, Church LW, Brown JM,
Schlamm HT, Oborska IT, Hilton F, Hodges MR. Voriconazole
versus a regimen of amphotericin B followed
by fluconazole for candidaemia in non-neutropenic
patients: a randomised non-inferiority trial. Lancet
2005;366:1435-42.
31. Charlier C, Hart E, Lefort A, Ribaud P, Dromer F, Denning
DW, Lortholary O. Fluconazole for the management of
invasive candidiasis: where do we stand after 15 years? J
Antimicrob Chemother 2006;57:384-410.
32. Perfect JR. Antifungal resistance: the clinical front.
Oncology (Williston Park) 2004;18(14 Suppl 13):15-22.
33. Playford EG, Webster AC, Sorrell TC, Craig JC. Antifungal
agents for preventing fungal infections in non-neutropenic
critically ill and surgical patients: systematic
review and meta-analysis of randomized clinical trials. J
Antimicrob Chemother 2006;57:628-38 (review).
34. Vazquez JA, Sobel JD. Anidulafungin: a novel echinocandin.
Clin Infect Dis 2006;43(2):215-22 (Review)
35. Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden
LR, Dmoszynska A, Cornely OA, Bourque MR, Lupinacci
RJ, Sable CA, dePauw BE. Caspofungin versus liposomal
amphotericin B for empirical antifungal therapy in
patients with persistent fever and neutropenia. N Engl J
Med 2004; 351:1391-402.
36. Neckers L, Neckers K. Heat-shock protein 90 inhibitors
as novel cancer chemotherapeutics - an update. Expert
Opin Emerg Drugs 2005;10:137-49. Review.
37. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V,
Kung AL, Davies FE, Morgan G, Akiyama M, Shringarpure
R, Munshi NC, Richardson PG, Hideshima T, Chauhan
D, Gu X, Bailey C, Joseph M, Libermann TA, Rosen NS,
Anderson KC. Antimyeloma activity of heat shock protein-90
inhibition. Blood 2006;107:1092-100.
38. Chiosis G, Rodina A, Moulick K. Emerging Hsp90 inhibitors:
from discovery to clinic. Anticancer Agents Med
Chem 2006;6:1-8 (review).
39. Whitesell L, Lindquist SL. HSP90 and the chaperoning
of cancer. Nat Rev Cancer 2005;5:761-72 (review).
40. Thomas X, Campos L, Le QH, Guyotat D. Heat shock proteins
and acute leukemias. Hematology. 2005;10:225-35
(review).
41. Cowen LE, Lindquist S. Hsp90 potentiates the rapid
evolution of new traits: drug resistance in diverse fungi.
Science 2005;309:2185-89
42. Heitman J. Cell biology. A fungal Achilles’ heel. Science
2005;309:2175-6.
43. Matthews RC, Rigg G, Hodgetts S, Carter T, Chapman
C, Gregory C, Illidge C, Burnie J. Preclinical assessment
of the efficacy of Mycograb, a human recombinant
antibody against fungal HSP90. Antimicrob Agents
Chemother 2003;47:2208-16.
44. Matthews RC, Burnie JP. Human recombinant antibody
to HSP90: a natural partner in combination therapy.
Curr Mol Med 2005;5:403-11.
45. Nooney L, Matthews RC, Burnie JP. Evaluation of
Mycograb, amphotericin B, caspofungin, and fluconazole
in combination against Cryptococcus neoformans
by checkerboard and time-kill methodologies. Diagn
Microbiol Infect Dis 2005;51:19-29.
46. Matthews RC, Burnie JP. Recombinant antibodies: a
natural partner in combinatorial antifungal therapy.
Vaccine 2004;22:865-71. Review.
47. Burnie J, Matthews R. Genetically recombinant antibodies:
new therapeutics against candidiasis. Expert Opin
Biol Ther 2004;4:233-41. Review.
48. Burnie J, Matthews R. The role of antibodies against
hsp90 in the treatment of fungal infections. Drug
News Perspect 2003;16:205-10. Review.
49. Matthews R, Burnie J. Antifungal antibodies: a new
approach to the treatment of systemic candidiasis. Curr
Opin Investig Drugs 2001;2:472-6 (review).
50. Pachl J, Svoboda P, Jacobs F, Vandewoude K, van der
Hoven B, Spronk P, Masterson G, Malbrain M, Aoun
M, Garbino J, Takala J, Drgona L, Burnie J, Matthews R;
Mycograb Invasive Candidiasis Study Group. A randomized,
blinded, multicenter trial of lipid-associated
amphotericin B alone versus in combination with an
antibody-based inhibitor of heat shock protein 90
in patients with invasive candidiasis. Clin Infect Dis
2006;42:1404-13.
51. Casadevall A. The third age of antimicrobial therapy. Clin
Infect Dis 2006;42:1414-6.
594
neth j crit care • volume 10 • no 5 • october 2006